Drug intelligence / Profile preview

Donor CD34+ and CD3+ cells

Development stage: Phase 2
Lead developer: University of California, Los Angeles
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

This cellular therapy approach, developed by Dr. Jeffrey Veale at UCLA, is designed to induce immune tolerance in HLA-identical sibling kidney transplant recipients. The treatment involves the infusion of donor-derived, G-CSF mobilized, and Miltenyi-enriched CD34+ hematopoietic stem/progenitor cells (HSPCs) and CD3+ T cells. This infusion follows a specific conditioning regimen consisting of Total Lymphoid Irradiation (TLI) and rabbit anti-thymocyte globulin (rATG). The primary therapeutic goal is to establish stable mixed chimerism—a state where donor and recipient immune systems coexist—which allows for the complete withdrawal of maintenance immunosuppressive medications while preventing kidney transplant rejection.

Other names: Donor CD34+ + CD3+ cellsDonor-derived hematopoietic stem and T cellsGCSF-mobilized donor CD34+ and CD3+ cells

Beyond the preview

Go deeper on Donor CD34+ and CD3+ cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Donor CD34+ and CD3+ cells.

Explore the full profile